Velmari

Velmari is a prolonged-release combined oral contraceptive (COC) developed by Exeltis. It contains 2 mg of dienogest, a fourth-generation progestin with potent progestogenic and antiandrogenic effects, and 0.02 mg of ethinyl estradiol, a synthetic estrogen. Unlike traditional COCs that use immediate-release formulations, Velmari utilizes a prolonged-release mechanism for its active ingredients. The drug provides contraception primarily by suppressing ovulation through the inhibition of gonadotropin secretion via the hypothalamic-pituitary-ovarian axis. It was evaluated in Phase II clinical trials for its bleeding profile and safety, and it received marketing authorization in several European markets via the Nordic MPA in early 2024.

Brand names

Velmari

Other names

Dienogest/Ethinylestradiol Exeltis 2 mg/0.02 mg prolonged-release tablet